spacer
home > ebr > summer 2017 > qbd in action
PUBLICATIONS
European Biopharmaceutical Review

QbD in Action

Humans are living increasingly longer due to continuous delivery of new chemical and biological entities (NBEs) from the pharmaceutical industry as tested and approved drugs. Unfortunately, this does not necessarily mean we are living healthier lives. With preventable issues on the rise – such as obesity, where 13% of the world’s adult population are now classed as overweight, or our dependency upon antibiotics giving rise to antibiotic resistance – some will debate this. However, there is a growing trend to deliver drugs that will contribute to a healthier society through the reduction of diseases, including cancer, cardiovascular disease, infectious diseases and neurological disorders, to name but a few.

NBEs are considerably more complex than traditional small molecule-based drugs due to their production by living cells and being hundreds of times larger and inherently more complicated to manufacture, so the existence of numerous regulatory guidelines is no surprise. These serve to ensure safety as well as efficacy and revolve around the continuous monitoring of key critical quality attributes (CQAs) throughout the drug development lifecycle. Routine characterisation can include observation of some of these CQAs through tests, such as charge variant profiling and aggregate analysis.

Recently, there has been a substantial focus on quality by design (QbD), with a joint pilot study by the EMA and FDA concluding that both agencies are well-aligned regarding the implementation of QbD concepts from ICH Q8, 9 and 10. They also stated that both agencies are “currently exploring potential joint activities with specific focus on continuous manufacturing, additional emerging technologies, and expedited/accelerated assessments”. The attention on utilising powerful detection techniques such as high-resolution mass spectrometry (MS) is growing within the chemistry, manufacturing and control stages through to quality control (QC) and lot release stages due to the increased levels of accuracy and information obtainable.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Simon Cubbon is a Pharma and Biopharma Vertical Marketing Manager at Thermo Fisher Scientific. He has worked within the analytical instruments industry for over 10 years, holding a variety of positions, from applications scientist through to informatics product management. Simon studied for his PhD at the University of York, UK, where he investigated using LC-MS to study the metabolic profile of long bone fractures.
spacer
Simon Cubbon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius debuts the Intellicyt iQue3 at CYTO® 2019

Sartorius will be showcasing the latest addition to its cellular analysis portfolio on booth #103 at this year’s CYTO® conference and exhibition, with the launch of the Intellicyt iQue3. The event – which takes place in Vancouver, Canada, from June 22 to 26 – will give delegates the chance to explore a smarter way to perform flow cytometry experiments.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement